Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of Singulair (10 mg) and Xyzal (5 mg) in free combination and fixed-dose combination as HCP1102

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hanmi Pharmaceutical Company Limited
• Treatments: Levocetirizine; Montelukast

Criteria

Inclusion Criteria:

• Healthy male

• Age between 20 and 55

• Signed informed consent

Exclusion Criteria:

• Has a history of hypersensitivity to IP ingredients

• Hypotension or hypertension

• Has a history of acute infection within 14 days of screening